The global Tamiflu (Oseltamivir Phosphate) market consists of oral antiviral medication used for the treatment and prevention of influenza virus strains like influenza A and influenza B. Tamiflu works by inhibiting the neuraminidase enzyme essential for viral replication, thus preventing the spread of viral particles in the body. It is available in capsule and oral suspension dosage forms with proven efficacy in reducing the duration of influenza symptoms like fever, muscle ache, and cough by around a day. The favorable safety profile of Tamiflu along with recommendations by global health organizations for its use, especially in high-risk groups, has resulted in its widespread adoption across countries.
The global Tamiflu (Oseltamivir Phosphate) Market is estimated to be valued at US$ 464.4 Mn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the Tamiflu (Oseltamivir Phosphate) market is the steady increase in R&D investments for developing alternative antiviral drugs and vaccination strategies to manage seasonal and pandemic influenza. While Tamiflu remains the drug of choice currently, increasing drug resistance seen with viruses like 2009 H1N1 strain is prompting research for better treatment options. Several pharmaceutical companies are conducting clinical trials evaluating the efficacy of new neuraminidase inhibitors like laninamivir and peramivir as standalone therapies or in combination with Tamiflu. Improvements in current vaccination technologies and development of universal flu vaccines targeting non-variable regions of influenza virus are other research areas attracting funding. This diversification of research portfolio is anticipated to lead to more treatment choices and help overcome the limitations of existing influenza management regimens over the forecast period.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the Tamiflu (Oseltamivir Phosphate) market is low as large capital investments are required for R&D along with obtaining regulatory approvals.
Bargaining power of buyers: The bargaining power of buyers is high in this market as there are many established brands available for influenza treatment.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as raw materials for Tamiflu manufacturing are commoditized.
Threat of new substitutes: The threat of new substitutes is moderate as there are alternative treatment options available for influenza.
Competitive rivalry: The competitive rivalry in the Tamiflu market is high as the key players compete on the basis of pricing strategies and new product launches.
Key Takeaways
The Global Tamiflu (Oseltamivir Phosphate) Market Size is expected to witness high growth during the forecast period of 2023 to 2030. The global Tamiflu (Oseltamivir Phosphate) Market is estimated to be valued at US$ 464.4 Mn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030.
Regional analysis: North America region currently dominates the Tamiflu market and is expected to continue its dominance over the forecast period. This is attributed to increasing cases of influenza in the region. Asia Pacific region is anticipated to witness fastest growth in the market over the coming years backed by rising awareness regarding influenza treatment.
Key players: Key players operating in the Tamiflu (Oseltamivir Phosphate) market include HCA Healthcare, Ascension Health, Kaiser Permanente, and Mayo. These players are focusing on developing generic versions of Tamiflu to tap the increasing demand and gain more market share.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it